A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2012
At a glance
- Drugs Imagabalin (Primary) ; Paroxetine
- Indications Generalised anxiety disorder
- Focus Adverse reactions; Therapeutic Use
- 27 Nov 2012 Planned number of patients changed from 287 to 528.
- 10 Jul 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
- 09 Mar 2009 Planned number of patients changed from 528 to 287 as reported by ClinicalTrials.gov.